Inventor · disambiguated record
Sarah Kutscher
Also filed as: KUTSCHER SARAH
11 granted patents·3 pending applications·7 citations·filing 2018–2024
87Inventor score
Files withIMMATICS BIOTECHNOLOGIES GMBH14
Top patents by PatentIndex Score
14 records- 0196US11679147B2Method of eliciting a CD8+ cytotoxic response in hepatocellular carcinoma patients with a population of activated T cellsIMMATICS BIOTECHNOLOGIES GMBH·Filed 2022·Granted Jun 20, 2023·2 cites·20 claims
- 0296US11672848B2Method of eliciting a CD8+ cytotoxic response in hepatocellular carcinoma patients with a population of activated T cellsIMMATICS BIOTECHNOLOGIES GMBH·Filed 2022·Granted Jun 13, 2023·2 cites·20 claims
- 0396US11576956B2Peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2021·Granted Feb 14, 2023·2 cites·20 claims
- 0491US11786583B2Peptides and combination of peptides for use in immunotherapy against Hepatocellular carcinoma (HCC) and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2021·Granted Oct 17, 2023·1 cites·20 claims
- 0591US2024408166A1Peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (hcc) and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2024·Application pending·0 cites
- 0685US11779638B2Method of eliciting a CD8+ cytotoxic response in hepatocellular carcinoma patients with a population of activated T cellsIMMATICS BIOTECHNOLOGIES GMBH·Filed 2022·Granted Oct 10, 2023·0 cites·20 claims
- 0784US11559573B2Method of eliciting a CD8+ cytotoxic response in hepatocellular carcinoma patients with a population of activated T cellsIMMATICS BIOTECHNOLOGIES GMBH·Filed 2022·Granted Jan 24, 2023·0 cites·20 claims
- 0882US12121572B2Peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2021·Granted Oct 22, 2024·0 cites·19 claims
- 0982US12097248B2Peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2021·Granted Sep 24, 2024·0 cites·19 claims
- 1082US12076380B2Peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2021·Granted Sep 3, 2024·0 cites·19 claims
- 1182US12070491B2Peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2021·Granted Aug 27, 2024·0 cites·19 claims
- 1275US2020405831A1Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (hcc) and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2020·Application pending·0 cites
- 1370US11406693B2Peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2018·Granted Aug 9, 2022·0 cites·12 claims
- 1466US2018207252A1Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (hcc) and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2018·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Sarah Kutscher files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →